[A Multicenter Comparison Study on the Detection of BCR-ABL Tyrosine Kinase Domain Point Mutation]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2015 Dec 4

PMID 26632460

Citations 1

Authors

Yazhen Qin

Dongmei Wang

Chun Qiao

Hongjie Shen

Suxia Geng

Zeng Cao

Xiaojun Huang

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the accuracy and consistency of the detection of BCR-ABL tyrosine kinase domain point mutation among different laboratories.

Methods: Every one of 6 laboratories prepared 10 cDNA samples from tyrosine kinase inhibitors resistant BCR-ABL (P210 or P190) positive patients'bone marrow or peripheral blood. Each cDNA sample was divided into 6 aliquots and delivered to the laboratories. All 6 laboratories tested BCR-ABL point mutations of 60 samples according to their own protocols. Peking University People's Hospital analyzed the comparison results based on both the reports and sequencing chromatogram from all laboratories.

Results: All laboratories reported the same nucleotide and corresponding amino acid mutations in 37 samples (61.7%）. Of 60 samples, 53 had confirmed mutation types, and a total of 23 types were included; 1 had no mutation; mutation types of 6 samples could not be determined because of the big differences among chromatograms from different laboratories. Low percentages of mutants were significantly related to results inconsistency (P=0.008). Inconsistent result of one sample was caused by the unique chromatogram of the mutant L248V, and one by the non-coverage amplification of PCR product from different laboratories. Amplification was failed in 3 samples. Testing or sequencing mistakes occurred in 7 samples. The differences in the mutant percentages among laboratories were less than 20% in the 80.6% of samples with confirmed results. Low internal control gene copies (ABL<10 000) were significantly related to both failed amplification and big differences among chromatograms from different laboratories (P=0.005 and <0.001, respectively).

Conclusion: Problems in the clinical routine detection of BCR-ABL point mutation could be exposed and improvement could be achieved by sample exchange and comparison. Low percentage of mutant is the main reason which causes the discrepancy of BCR-ABL point mutation results among different laboratories.

Citing Articles

[Current status and challenges of diagnosis and monitoring of hematologic malignancies].

Qin Y, Huang X Zhonghua Xue Ye Xue Za Zhi. 2016; 36(12):985-8.

PMID: 26759097 PMC: 7342313. DOI: 10.3760/cma.j.issn.0253-2727.2015.12.001.

References

Druker B, Guilhot F, OBrien S, Gathmann I, Kantarjian H, Gattermann N . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23):2408-17. DOI: 10.1056/NEJMoa062867. View

Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K . High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002; 99(9):3472-5. DOI: 10.1182/blood.v99.9.3472. View

Wassmann B, Pfeifer H, Goekbuget N, Beelen D, Beck J, Stelljes M . Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006; 108(5):1469-77. DOI: 10.1182/blood-2005-11-4386. View

Qin Y, Lin Z, Cen J, Li X, Li Q, Cheng H . [A multicenter study on the validation of conversion factor for the conversion of BCR-ABL (P210) transcript levels to the international scale in chronic myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2014; 35(2):134-7. DOI: 10.3760/cma.j.issn.0253-2727.2014.02.016. View

Qin Y, Chen S, Jiang B, Jiang Q, Jiang H, Li J . Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Ann Hematol. 2010; 90(1):47-52. DOI: 10.1007/s00277-010-1039-5. View

Qin Y, Liu Y, Zhu H, Li J, Ruan G, Zhang Y . Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response. Int J Lab Hematol. 2008; 30(4):317-23. DOI: 10.1111/j.1751-553X.2007.00962.x. View

Baccarani M, Deininger M, Rosti G, Hochhaus A, Soverini S, Apperley J . European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6):872-84. PMC: 4915804. DOI: 10.1182/blood-2013-05-501569. View

Soverini S, de Benedittis C, Polakova K, Brouckova A, Horner D, Iacono M . Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood. 2013; 122(9):1634-48. DOI: 10.1182/blood-2013-03-487728. View

Soverini S, Hochhaus A, Nicolini F, Gruber F, Lange T, Saglio G . BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011; 118(5):1208-15. DOI: 10.1182/blood-2010-12-326405. View

10.

Jabbour E, Jones D, Kantarjian H, OBrien S, Tam C, Koller C . Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. 2009; 114(10):2037-43. PMC: 4186638. DOI: 10.1182/blood-2009-01-197715. View

11.

Soverini S, de Benedittis C, Papayannidis C, Paolini S, Venturi C, Iacobucci I . Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in.... Cancer. 2014; 120(7):1002-9. DOI: 10.1002/cncr.28522. View

12.

Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A . Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006; 12(24):7374-9. DOI: 10.1158/1078-0432.CCR-06-1516. View

13.

Gruber F, Hjorth-Hansen H, Mikkola I, Stenke L, Johansen T . A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib. Leukemia. 2006; 20(11):2057-60. DOI: 10.1038/sj.leu.2404400. View

14.

Gorre M, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P . Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293(5531):876-80. DOI: 10.1126/science.1062538. View